- PROJECT 4 Emerging evidence has implicated transcriptional coactivators and enhancer elements as having a central role in the pathogenesis of human cancer. The research outlined in Project 4 will develop transcriptional coactivators as proteins that support the aberrant capabilities of cancer cells, thus revealing a novel class of epigenetic drug targets in oncology. This research will explore the role of SWI/SNF and TFIID coactivator complexes in the pathogenesis of Acute Myeloid Leukemia (AML) and will identify novel roles for coactivators in supporting the progression of late-stage Pancreatic Ductal Adenocarcinoma (PDA).
The first Aim of this proposal will analyze the anti-leukemia effects of chemical inhibitors of the bromodomain of BRD9, which are novel compounds we generated in collaboration with Boehringer-Ingelheim. The major objective of this research will be to develop drug combinations that augment the therapeutic effects of BRD9 inhibition in AML. This will include use of CRISPR-scanning and domain-focused CRISPR screening, which are recently developed genetic tools to allow deep mechanistic investigation of endogenous protein complexes and to reveal opportunities for drug repurposing. This research has a direct potential to motivate clinical studies of novel drug combinations in AML patient populations.
The second Aim will develop the TAF12/TFIID complex as a novel dependency in AML and reveal its underlying mechanism in supporting oncogene-mediated leukemic transformation. This will also include identifying suitable routes for direct chemical inhibition of this complex, an objective that has yet to be achieved in the cancer epigenetics field, largely owing to our incomplete understanding about how TFIID supports cancer pathogenesis.
The third Aim of Project 4 will be to understand how modulation of nucleosome structure by writers, readers, and erasers of post-translational histone marks might endow PDA cells with the capacity to undergo metastasis. This will include domain- focused CRISPR screening to interrogate chromatin regulators that allow distal metastasis in mouse models of PDA. Since early metastasis is a major contributor to the high mortality of PDA patients, this research may significantly impact our basic understanding of the lethal form of this disease, and carries the potential for revealing epigenetic drug targets for this malignancy. Importantly, the research outlined in Project 4 will provide a deep mechanistic investigation of transcriptional mechanisms that support AML and PDA, which will rely on extensive use of epigenomic tools (e.g. ChIP-seq-based measurement of enhancer activity), and biochemical approaches. Project 4 will also feature extensive collaborations with the other Projects and Cores to evaluate molecular mechanisms and in vivo biology of malignant cells. This basic research will reveal novel vulnerabilities in lethal malignancies, which could provide new routes for therapy.
- PROJECT 4 This research will develop a new class of therapeutic targets for the treatment of two lethal cancers: acute myeloid leukemia and pancreatic cancer. Experiments will provide insight into how novel therapies exert their harmful effects on cancer cells and will provide pre-clinical proof-of-concept in animal models that could justify clinical investigation in cancer patients.
| On, Kin Fan; Jaremko, Matt; Stillman, Bruce et al. (2018) A structural view of the initiators for chromosome replication. Curr Opin Struct Biol 53:131-139 |
| Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381 |
| Shamay, Yosi; Shah, Janki; I??k, Mehtap et al. (2018) Quantitative self-assembly prediction yields targeted nanomedicines. Nat Mater 17:361-368 |
| Tramentozzi, Elisa; Ferraro, Paola; Hossain, Manzar et al. (2018) The dNTP triphosphohydrolase activity of SAMHD1 persists during S-phase when the enzyme is phosphorylated at T592. Cell Cycle 17:1102-1114 |
| Arun, Gayatri; Diermeier, Sarah D; Spector, David L (2018) Therapeutic Targeting of Long Non-Coding RNAs in Cancer. Trends Mol Med 24:257-277 |
| Tarumoto, Yusuke; Lu, Bin; Somerville, Tim D D et al. (2018) LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia. Mol Cell 69:1017-1027.e6 |
| Xu, Yali; Milazzo, Joseph P; Somerville, Tim D D et al. (2018) A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia. Cancer Cell 33:13-28.e8 |
| Huang, Yu-Han; Klingbeil, Olaf; He, Xue-Yan et al. (2018) POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev 32:915-928 |
| Livshits, Geulah; Alonso-Curbelo, Direna; Morris 4th, John P et al. (2018) Arid1a restrains Kras-dependent changes in acinar cell identity. Elife 7: |
| Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129 |
Showing the most recent 10 out of 610 publications
